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To the Editor 
Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory 
syndrome coronavirus 2 (SARS CoV-2), was declared a global public health emergency on 30 
January 2020. Emerging data suggests that COVID-19 has extrapulmonary manifestations and 
complications, subsequently leading to multiorgan failure and death. Common cardiovascular and 
renal complications reported to be associated with COVID-19 include myocardial injury, heart failure, 
acute kidney injury and electrolyte disturbances.(1, 2) In addition to the observation that older 
patients, males and those with pre-existing comorbidities such as cardiovascular disease, diabetes, 
chronic kidney disease and chronic liver disease are at highest risk for severe illness or death,(3, 4) 
COVID-19 complications have been shown to correlate with the disease severity or mortality.(5, 6) 
Emerging data also suggests COVID-19 contributes to adverse hepatic manifestations such as acute 
hepatic injury. Wang and colleagues in their recent published study to investigate characteristics and 
prognostic factors in 339 elderly patients with COVID-19, a high proportion of severe and critical 
cases were observed as well as a high fatality rate.(7) Apart from cardiovascular complications such 
as acute cardiac injury, arrhythmia and cardiac insufficiency, 28.7% of patients were reported to have 
developed liver enzyme abnormalities. Coronavirus disease 2019 is still evolving; its exact clinical 
course, severity and complications are still not completely clear. Given the sparse data, the hepatic 
manifestations and complications of COVID-19 are not clearly defined. In this context, we sought to 
address the following questions using a systematic meta-analysis: (i) what are the hepatic 
manifestations and complications of COVID-19?; (ii) what is the prevalence of hepatic manifestations 
and incidence of hepatic complications?;  and (iii) are patients with pre-existing hepatic conditions 
more susceptible to these complications? 
The protocol for this review was registered in the PROSPERO International prospective 
register of systematic reviews (CRD42020190354) and the review was conducted in accordance with 
PRISMA and MOOSE guidelines (Supplementary Materials 1-2). Published studies reporting on 
hepatic complications following admission in patients hospitalised with COVID-19 and/or hepatic 
manifestations during admission were sought MEDLINE, Embase, and The Cochrane library from 




prevalence of comorbidities (eg, pre-existing chronic liver disease), prevalence of hepatic 
manifestations and incidence of hepatic complications across studies with their 95% confidence 
intervals (CIs) were pooled using Freeman-Tukey variance stabilising double arcsine transformation 
and random-effects models. All statistical analyses employed STATA release MP 16 (StataCorp LP, 
College Station, TX, USA) 
Nineteen retrospective cohort studies comprising of 15,103 patients with COVID-19 were 
included (Table 1; Supplementary Materials 4-5). Fourteen studies were based in China and five in 
the USA. The average age at baseline ranged from 32 to 71 years. 
 In pooled analysis of 10 studies, the prevalence of pre-existing chronic liver disease (95% 
CI) in COVID-19 patients was 1.9% (0.5-3.8) (Supplementary Material 6). The prevalence (95% 
CI) of pre-existing liver cirrhosis (3 studies), hepatitis B (3 studies) and hepatitis C (2 studies) was 
0.4% (0.0-1.8), 0.9% (0.1-2.5) and 0.3% (0.2-0.5) respectively (Supplementary Material 7). The 
prevalence (95% CI) of hepatic manifestations on admission: elevated alanine aminotransferase 
(ALT) (9 studies), elevated aspartate aminotransferase (AST) (8 studies), low albumin (2 studies) and 
elevated total bilirubin (3 studies) was 26.6% (15.8-39.0), 37.2% (20.3-55.8), 45.6 (40.5-50.8) and 
18.2% (10.0-28.1) respectively (Supplementary Material 8).  
Over hospital stays ranging from 2 to 28 days, the pooled incidence was 69.1% (67.3-70.9) 
for elevated ALT (2 studies); 34.8% (16.2-56.0) for elevated AST; 11.2% (6.4-17.1) for acute hepatic 
injury (15 studies) and 7.9% (5.9-10.2) for hypoproteinaemia (n=2 studies) (Figure 1A). Subgroup 
analyses suggested that the incidence of acute hepatic injury was higher in Chinese populations and 
groups with a higher prevalence of pre-existing chronic liver disease; however, the incidence of acute 
hepatic injury was similar in older (≥60 years) or younger age (<60 years) groups (Figure 1B).  
Based on up-to-date published evidence, the common hepatic complications of COVID-19 
are liver enzyme abnormalities (particularly the aminotransferases) followed by acute hepatic injury 
and hypoproteinaemia. Common hepatic manifestations on admission are elevated levels of ALT, 
AST and total bilirubin as well as low albumin levels. In contrast to a previous study which reported 
that about 2-11% of patients with COVID-19 have liver comorbidities,(8) the current review suggests 




is controversy regarding the causes of liver injury in COVID-19,(8) the following mechanistic 
pathways have been proposed: (i) drug-induced during treatment; (i) direct injury to the liver due to 
COVID-19 hepatitis; (ii) COVID-19 induced myositis causing elevations in circulating levels of liver 
enzymes; (iii) binding of SARS CoV-2 directly to angiotensin-converting enzyme 2 (ACE2) positive 
rich cholangiocytes and causing liver damage; (iv) hepatic congestion due to high levels of positive 
end expiratory pressure during mechanical ventilation; and (v) aggravation of liver injury by SARS 
CoV-2 in patients with pre-existing viral hepatitis.(4) The current findings suggest that patient groups 
with higher prevalence of pre-existing chronic liver disease have higher incidence of acute hepatic 
injury. 
Patients with pre-existing liver dysfunction appear to have worse outcomes in COVID-19,(8) 
which has been attributed to their immunocompromised status.(8) Hepatic complications such as 
acute hepatic injury have also been shown to be associated with increased risk of severe COVID-19 
and fatal outcomes.(9) Liver injury is commonly characterised by markedly elevated levels of the 
aminotransferases and evidence suggests that elevated levels of these enzymes are associated with 
greater risk of severe disease and mortality.(4) Hepatic dysfunction is associated with systemic 
disturbances such as activation of the coagulation and fibrinolytic cascades, depressed platelet counts, 
increased neutrophil counts, decreased lymphocyte counts and increased ferritin levels,(10) which 
disrupt innate immune regulation. More intensive surveillance of markers of hepatic dysfunction is 
needed for patients who are admitted, to enable early and individually tailored therapeutic approaches.  
Inherent limitations of this review included: (i) low methodological quality and sample sizes 
of included studies, which was not unexpected given the urgency to report and  gain a better 
understanding of COVID-19; (ii) potential for selective reporting by some of the studies; (iii) 
definitions of acute hepatic injury were not reported by studies, hence it is unknown if this was 
consistent across studies; (iv) timing for assessment of hepatic markers may vary between studies, 
hence estimates may be biased; and (v) the potential possibility of patient overlap given that the 
majority of studies were conducted from China.(4) 
Synthesis of the current literature suggests that liver enzyme abnormalities, acute hepatic 




COVID-19. Intensive monitoring of markers of these complications and management during 
admission could help in the prediction of favourable outcomes. The causes of these hepatic 
complications need further elucidation. 
 
Conflict of interest 
None. 
Acknowledgements 
SKK acknowledges support from the NIHR Biomedical Research Centre at University Hospitals 
Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication 
are those of the authors and not necessarily those of the NHS, the National Institute for Health 
Research or the Department of Health and Social Care. These sources had no role in design and 
conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, 






1. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: A systematic review and 
meta-analysis. Ann Med. 2020 (In Press). 
2. Kunutsor SK, Laukkanen JA. Cardiovascular complications in COVID-19: A systematic 
review and meta-analysis. J Infect. 2020 Jun 3. PubMed PMID: 32504747. Epub 2020/06/07. 
3. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020 
Mar 28;395(10229):1014-5. PubMed PMID: 32197108. Pubmed Central PMCID: PMC7138151. 
Epub 2020/03/21. 
4. Kunutsor SK, Laukkanen JA. Markers of liver injury and clinical outcomes in COVID-19 
patients: A systematic review and meta-analysis. J Infect. 2020 May 28. PubMed PMID: 32474033. 
Pubmed Central PMCID: PMC7255758. Epub 2020/06/01. 
5. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal 
Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. 
PubMed PMID: 32219356. Pubmed Central PMCID: PMC7101506. Epub 2020/03/29. 
6. Wang X, Fang X, Cai Z, Wu X, Gao X, Min J, et al. Comorbid Chronic Diseases and Acute 
Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 
Patients: A Systemic Review and Meta-Analysis. Research (Wash D C). 2020;2020:2402961. 
PubMed PMID: 32377638. Pubmed Central PMCID: PMC7187729. Epub 2020/05/08. 
7. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly 
patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020 Mar 30. 
PubMed PMID: 32240670. Pubmed Central PMCID: PMC7118526. Epub 2020/04/03. 
8. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet 
Gastroenterol Hepatol. 2020 May;5(5):428-30. PubMed PMID: 32145190. Pubmed Central PMCID: 
PMC7129165. Epub 2020/03/08. 
9. Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. Longitudinal association between 
markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020 May 2. PubMed 
PMID: 32359177. Epub 2020/05/03. 
10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 






Table 1. Characteristics of included studies 
Author, year of 
publication 
Source of data Country Dates of data collection Mean/median 
age (years) 




Hepatic complications NOS 
Aggarwal, 2020 UnityPoint Clinic USA March - April 2020 67.0 75.0 2.0 16 Acute hepatic injury 4 
Arentz, 2020 Evergreen Hospital in Kirkland, Washington USA Feb - March 2020 70.0 52.0 5.2 21 Acute hepatic injury 4 
Chen, 2020 Tongji Hospital in Wuhan China Jan - Feb 2020 62.0 62.0 13.0 274 Acute hepatic injury 4 
Cao, 2020 Zhongnan Hospital of Wuhan University China Jan - Feb 2020 54.0 52.0 11.0 102 Acute hepatic injury; liver 
enzyme abnormalities 
4 
Du, 2020 Hannan Hospital and Wuhan Union Hospital China Jan - Feb 2020 65.8 72.9 10.1 85 Acute hepatic injury 4 
Guo, 2020 Seventh Hospital of Wuhan City China Jan - Feb 2020 58.5 48.7 16.3 187 Acute hepatic injury 5 
Jin, 2020 Zhejiang province China Jan – Feb 2020 45.2 50.8 NR 651 Acute hepatic injury 6 
Liu, 2020 Shenzhen Third People’s hospital China Dec 2019 - Jan 2020 61.0 66.7 8.6 12 Hepatic insufficiency 4 
Phipps, 2020 New York-Presbyterian network USA March – April 2020 65.0 57.0 6.0 2,273 Liver enzyme abnormalities 6 
Price-Haywood, 
2020 (W) 
Ochsner Health in Louisiana USA March – April, 2020 55.5 45.7 7.0 1,030 Acute hepatic injury 6 
Price-Haywood, 
2020 (B) 
Ochsner Health in Louisiana USA March – April, 2020 53.6 37.7 6.0 2,451 Acute hepatic injury 6 
Richardson, 2020 Hospitals in New York USA March - April 2020 63.0 60.3 4.5 5,700 Acute hepatic injury 4 
Shi,2020 Renmin Hospital of Wuhan University China Jan - Feb 2020 64.0 49.3  NR 416 Hypoproteinaemia 6 
Wang, 2020 Renmin Hospital of Wuhan University China Jan - Feb 2020 71.0 49.0 28.0 339 Liver enzyme abnormalities 4 
Xi, 2020 Fourth People’s Hospital of Qinghai Province; Third People’s 
Hospital of Xining 
China Jan – April 2020 32.0 67.0 13.5 18 Acute hepatic injury 4 
Yang, 2020 Wuhan Jin Yin-tan hospital China Dec 2019 - Jan 2020 59.7 67.0 10.0 52 Liver dysfunction 4 
Zhang, 2020 Huanggang Central Hospital; The Second Affiliated Hospital 
of Shandong First Medical University 
China Jan – Feb 2020 48.3 55.7 10.2 194 Low albumin; elevated 
aminotransferases 
4 
Zhao, 2020 Jingzhou Central Hospital China Jan – Feb 2020 46.0 53.8 NR 91 Acute hepatic injury 4 
Zhao, 2020b Shouyi and East districts of Renmin Hospital of Wuhan 
University 
China Jan – Feb 2020 61.0 46.6 7.0 1000 Acute hepatic injury 4 
Zhou, 2020 Jinyintan Hospital & Wuhan Pulmonary Hospital China Dec - Jan 2020 56.0 62.0 11.0 191 Hypoproteinaemia 5 
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No Checklist item 
Reported on page 
No 
Title 




2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, 
conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, 
provide registration information including registration number 
Methods 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years 
considered, language, publication status) used as criteria for eligibility, giving rationale 
Methods 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched 
Methods 




Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
Methods 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis 
Methods 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, 
selective reporting within studies) 
Methods 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 






18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up 
period) and provide the citations 
Results, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). Results  
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency Results, Figure 1; 
Supplementary 
material 6-8 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 






24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as 
incomplete retrieval of identified research, reporting bias) 
Discussion 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role 





Supplementary Material 2. MOOSE checklist  
 
Hepatic manifestations and complications of COVID-19: A systematic review and meta-analysis 
 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition Hepatic manifestations of COVID-19 are not clearly defined. 
 Hypothesis statement (i) What are the hepatic manifestations and complications associated with 
COVID-19? 
(ii) What is the prevalence of hepatic manifestations and incidence of hepatic 
complications?  
(iii) Are patients with pre-existing hepatic conditions more susceptible to 
these hepatic complications? 
 
 Description of study outcomes Hepatic complications 
 Type of exposure  Prevalence and incidence estimates 
 Type of study designs used Observational cohort designs and clinical studies 
 Study population Adult patients with COVID-19 
Reporting of search strategy should include  
 Qualifications of searchers Setor K. Kunutsor, PhD 
 Search strategy, including time period 
included in the synthesis and keywords 
Time period: from inception to 15 June 2020 
The detailed search strategy can be found in Supplementary material 3 
 Databases and registries searched MEDLINE, Embase and The Cochrane Library 
 Search software used, name and version, 
including special features 
OvidSP was used to search Embase and MEDLINE 
EndNote X9 used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  The 
citation list for excluded studies are available on request. 
 Method of addressing articles published 
in languages other than English 
Not applicable 
 Method of handling abstracts and 
unpublished studies 
Not applicable 
 Description of any contact with authors None 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled for 
assessing the hypothesis to be tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and coding of 
data 
Data extracted from each of the studies were relevant to the population 
characteristics, study design, exposure, and outcome. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis of 
different adjustment levels and performed sub-group analyses to evaluate 
differences in the overall estimates according to levels of adjustment. 
 Assessment of study quality, including 
blinding of quality assessors; 
stratification or regression on possible 
predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa Scale 
using pre-defined criteria namely: population representativeness, 
comparability (adjustment of confounders), ascertainment of outcome. 
Sensitivity analyses by several quality indicators such as study size, duration 
of follow-up, and adjustment factors. 
 Assessment of heterogeneity Results 
 Description of statistical methods in 
sufficient detail to be replicated 
Described in methods section 
 Provision of appropriate tables and 
graphics 
Table 1; Figure 1; Supplementary materials 6-8 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Supplementary materials 6-8 
 Table giving descriptive information for 
each study included 
Table 1 
 Results of sensitivity testing 
 
Not applicable  
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates 
Reporting of discussion should include  






 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria in 
methods section. 
 Assessment of quality of included studies Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative explanations 
for observed results 
Discussion 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend large-scale studies when more data becomes available 






Supplementary Material 3: MEDLINE literature search strategy 
 
1     COVID-19.mp. (7239) 
2     SARS-CoV-2.mp. (2017) 
3     exp Liver Diseases/ (549145) 
4     acute liver injury.mp. (2471) 
5     acute hepatic injury.mp. (366) 
6     liver dysfunction.mp. (7648) 
7     exp Liver Cirrhosis/ (88730) 
8     chronic liver disease.mp. (15325) 
9     exp Hypoproteinemia/ (2827) 
10     1 or 2 (7412) 
11     3 or 4 or 5 or 6 or 7 or 8 or 9 (559902) 
12     10 and 11 (24) 
13     limit 12 to (english language and humans and yr="2019 -Current") (15) 
 





Supplementary Material 4: Selection of studies included in the meta-analysis 
77 Potentially relevant citations identified
From MEDLINE, Embase and reference list 
of relevant studies
43 excluded on the basis of title 
and/ or abstract
5 Articles excluded due to:
4 Outcome not relevant
1 Review
19 Articles included in review
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Supplementary Material 6: Prevalence of pre-existing chronic liver disease in COVID-19 patients 
 

















































































































































































































































































ALT, alanine aminotransferase; AST, aspartate aminotransferase; B, black; CI, confidence interval (bars); W, 
white 
 
 
